A new study “The Prevalence of Age-Related Macular Degeneration in the United States In 2019” published in JAMA Ophthalmology, found that in 2019, there were an estimated 19.83 million Americans were living with some form of age-related macular degeneration (AMD) in 2019. This is an increase of approximately more than 2.75 times previous estimates (which used a more [Read More]
News
Join Us for a Free Webinar on the New Living Well With Low Vision
Are you living with vision loss and blindness, have a family member or loved one with vision loss, or work with individuals with vision loss? If you answered yes, please join us on November 16 from 6:00-6:45pm Eastern to: Understand what low vision is and how trusted information and resources can ease the burden of [Read More]
Susvimo implant for Wet AMD Voluntarily Recalled
Susvimo, previously called Port Delivery System with ranibizumab (Lucentis), was FDA-approved on October 21, 2021, for intravitreal use via ocular implant for the treatment of people with wet (neovascular) age-related macular degeneration (AMD). Now, one year later, Genentech has announced that it is voluntarily recalling the implant and the insertion tool in the U.S. As [Read More]
Doing Nothing (When There’s Nothing To Do)
Remember the Saturdays of our childhoods, when hours were forever, and the day was interminable? When our young worlds turned so slowly that super cool ideas for the day became passé by lunch, leaving us facing a void of unexpected idleness? What did we do with all that extra time? We probably spent it trying [Read More]
Samsara Vision Announces Clinical Trial for New Investigational Implantable Miniature Telescope
CONCERTO clinical trial is seeking participants to evaluate the new investigational SING IMT Long-time members of our AMD community may remember FDA approval in 2010 of a device from Samsara Vision (formerly VisionCare, Inc.) called the Implantable Miniature Telescope (IMT). This device is a tiny telescope which provides precision images, magnification of up to 3 times, [Read More]